Table 2.
Pharmacokinetics of fosmidomycin and clindamycin analysed by non-compartmental model in patients with acute uncomplicated falciparum malaria. Data are presented as median (95% C.I.) values.
| Pharmacokinetic parameters | Fosmidomycin monotherapy (N = 15) | Fosmidomycin + Clindamycin (N = 18) | |
| Fosmidomycin | Clindamycin | ||
| Cmax (μg/ml) | 4.58 (2.32–6.77) | 5.86 (2.79–12.52) | 7.34 (4.88–12.73) |
| tmax (hr) | 2 (1–4) | 2 (1–4) | 1 (1–2) |
| Ctrough-obs (μg/ml) | 1.90 (0.92–2.99) | 0.40 (0.0–2.01) | 1.32 (0.39–3.42) |
| Cmin-ave (μg/ml) | 1.47 (0.06–9.96) | 1.06 (0.20–2.98) | 0.17 (0.01–0.78) |
| Cmax-ave (μg/ml) | 7.22 (1.52–15.84) | 8.67 (4.21–14.23) | 6.63 (3.96–9.52) |
| Css-ave (μg/ml) | 3.74 (3.18–12.52) | 2.93 (1.97–6.98) | 1.91 (1.20–3.06) |
| Fluctuation | 5.1 (1.6–47.6) | 10.5 (3.6–40.3) | 1.1 (0.7–1.6) |
| AUC0, t (μg.hr/ml) | 22.91 (12.65–33.32) | 35.00 (20.41–78.90) | 31.80 (15.84–370.67) |
| AUC0,((μg.hr/ml) | 29.7 (25.06–100.16) | 39.13 (24.29–85.55) | 31.91 (19.28–50.49) |
| λ Z (/hr | 0.201 (0.06–0.48) | 0.196 (0.107–0.308) | 0.272 (0.156–0.464) |
| T1/2z (/hr) | 3.4 (1.4–11.8) | 3.5 (2.2–6.5) | 2.6 (1.5–4.4) |
| VZ/F (l) | 211.40 (96.84–823.04) | 116.21 (69.94–267.45)a | 67.50 (46.56–135-87) |
| CL/F (l/hr) | 40.08 (11.97–47.18) | 25.94 (10.74–38.13)b | 18.77 (11.77–30.12) |
a = Statistically significant difference with monotherapy with p-value = 0.004
b = Statistically significant difference with monotherapy with p-value < 0.0001